Carisma Therapeutics, Inc.
$0.47
-0.02 (-4.27%)
CARM Price Chart
| Basic | |
|---|---|
| Market Cap | $20.54M |
| Price | $0.47 |
| 52 Week Range | 0.38-2.77 |
| Beta | 1.56 |
| Margins | |
| Gross Profit Margin | 94.31% |
| Operating Profit Margin | -262.82% |
| Net Profit Margin | -312.69% |
| Valuation (TTM) | |
| P/E Ratio | -0.45 |
| Price to Sales Ratio | 1.41 |
| Price to Book Ratio | -0.62 |
| PEG Ratio | -0.03 |
Industry
Biotechnology
Sector
Healthcare
Full-Time Employees
107
Website
IPO Date
2014-02-06T00:00:00.000Z
Description
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Phone
484 899 0326
Address
3675 Market St., Philadelphia, PA, 19104, US
CIK
0001485003